CeNeRx raises $13M as it preps for Phase II

Research Triangle Park-based CeNeRx BioPharma has raised $13 million to conduct Phase II trials of its experimental antidepressant. Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the Series C round.

CeNeRx is preparing to start a Phase II trial TriRima, the company's lead drug for treatment-resistant depression. "These funds will support the Phase II trial of TriRima as monotherapy for treatment-resistant depression," says CeNeRx CEO Barry Brand. "We are pleased with the continuing confidence and support of our investors and look forward to advancing the CeNeRx pipeline."

- check out the release from CeNeRx

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.